- Home
- DAN vs DNLI Comparison
DAN vs DNLI Comparison
Compare DAN & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAN | DNLI |
|---|---|---|
| Founded | 1904 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | DAN | DNLI |
|---|---|---|
| Price | $23.50 | $17.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | $26.40 | ★ $32.58 |
| AVG Volume (30 Days) | ★ 2.2M | 1.8M |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $9,957,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.05 | $3,993.60 |
| P/E Ratio | $51.58 | ★ N/A |
| Revenue Growth | ★ 17.78 | N/A |
| 52 Week Low | $10.11 | $10.57 |
| 52 Week High | $23.92 | $24.35 |
Technical Indicators
Market Signals| Indicator | DAN | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 64.42 | 44.93 |
| Support Level | $22.39 | $16.66 |
| Resistance Level | $23.25 | $18.30 |
| Average True Range (ATR) | 0.74 | 0.97 |
| MACD | 0.09 | -0.34 |
| Stochastic Oscillator | 86.99 | 8.86 |
Price Performance
Historical ComparisonAbout DAN Dana Incorporated
Dana Inc is engaged in the designing and manufacturing of efficient propulsion and energy-management solutions that power vehicles and machines in all mobility markets across the globe. The company has four operating segments: Light Vehicles, Power Technologies, Commercial Vehicle, and Off-Highway. The Light Vehicles segment generates the majority portion of revenue by providing products to support light vehicle OEMs. Its products are designed for light trucks, SUVs, CUVs, vans, and passenger cars.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.